Berberine as a potential therapeutic agent in the treatment of acute pancreatitis

Authors

  • Aleksandra Tarasiuk Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland
  • Leon Pawlik Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland
  • Jakub Fichna Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Poland

DOI:

https://doi.org/10.18388/pb.2019_278

Abstract

Berberine (BRB) is a compound belonging to the group of isoquinoline alkaloids of plant origin that has long been used in traditional chinese medicine (TMC). Due to, among others anti-inflammatory properties BRB is a potential therapeutic in the treatment of acute pancreatitis (OZT). In a study in the mouse model of L-arginine-induced acute pancreatitis, we showed that BRB administered by the intravenous route at 0.1 and 0.5 mg / kg body weight significantly reduces the level of myeloperoxidase activity (an indicator of inflammation) in the pancreas and lungs. Promising results point to the need for larger, randomized studies to assess the long-term efficacy and side effects of BRB therapy.

Downloads

Download data is not yet available.

Downloads

Published

2019-10-01

Issue

Vol. 65 No. 3 (2019)

Section

Articles

License

All journal contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made, ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. There are no additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Copyright for all published papers © stays with the authors.

Copyright for the journal: © Polish Biochemical Society.